Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.

摘要

The emergence of resistance of Mycobacterium tuberculosis to fluoroquinolones in patients with newly diagnosed infection has been a concern, especially in patients who have prior exposure to fluoroquinolones.1 Furthermore, the usage of fluoroquinolones in community-acquired infection has been reported to delay the diagnosis of tuberculosis (TB).2'3 The development of a new quinolone that retains the antibacterial activity spectrum of classic fluoroquinolones but with a relatively low activity against M. tuberculosis might have a role to play in removing the concern of potentially delaying the diagnosis of TB.